Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP2A known ✓ | P11388 | 1/20 | 0.61 |
| ▸ | TOP2B known ✓ | Q02880 | 1/20 | 0.61 |
| ▸ | PRSS1 | P07477 | 7/20 | 0.78 |
| ▸ | PRSS3 | P35030 | 4/20 | 0.78 |
| ▸ | F2 | P00734 | 3/20 | 0.78 |
| ▸ | APEX1 | P27695 | 1/20 | 0.78 |
| ▸ | LMNA | P02545 | 2/20 | 0.74 |
| ▸ | PLAU | P00749 | 2/20 | 0.72 |
| ▸ | BLM | P54132 | 1/20 | 0.72 |
| ▸ | MASP2 | O00187 | 1/20 | 0.72 |
| ▸ | THPO | P40225 | 1/20 | 0.72 |
| ▸ | PRSS2 | P07478 | 3/20 | 0.68 |
| ▸ | C1S | P09871 | 1/20 | 0.68 |
| ▸ | RECQL | P46063 | 1/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.68 |
| ▸ | F10 | P00742 | 2/20 | 0.67 |
| ▸ | F12 | P00748 | 1/20 | 0.67 |
| ▸ | F7 | P08709 | 1/20 | 0.67 |
| ▸ | F3 | P13726 | 1/20 | 0.67 |
| ▸ | PKM | P14618 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL30999366 | 1.00 | PRSS1 (0.78) | PRSS1PRSS3F2APEX1LMNA | |
| SCHEMBL537030 | 0.96 | LMNA (0.77) | PRSS1PRSS3F2APEX1LMNA | |
| Hydrochloric Acid SCHEMBL29182280 | 0.91 | PRSS1 (0.67) | PRSS1PRSS3F2APEX1LMNA | |
| Hydrochloric Acid SCHEMBL236095 | 0.88 | PRSS1 (1.00) | PRSS1PRSS3F2APEX1LMNA | |
| Hydrochloric Acid SCHEMBL4279969 | 0.88 | LMNA (0.94) | PRSS1PRSS3F2APEX1LMNA | |
| Hydrochloric Acid SCHEMBL538862 | 0.88 | PRSS1 (1.00) | PRSS1PRSS3F2APEX1LMNA | |
| SCHEMBL8973288 | 0.87 | WDR5 (0.80) | PRSS1PRSS3F2APEX1LMNA | |
| SCHEMBL394218 | 0.87 | WDR5 (0.80) | PRSS1PRSS3F2APEX1LMNA | |
| Hydrochloric Acid SCHEMBL8652339 | 0.86 | F2 (0.61) | PRSS1PRSS3F2APEX1LMNA | |
| Hydrochloric Acid SCHEMBL1033555 | 0.86 | LMNA (1.00) | PRSS1PRSS3F2APEX1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120082052-A | Mono-atom iron anchored covalent triazine skeleton and green synthesis method and application thereof | 杭州师范大学 | 2025-06-03 | — | — | CN | claimed |
| CN-115386083-A | 3, 4-ethylenedioxythiophene covalent triazine framework and synthesis method and application thereof | 河南农业大学 | 2022-11-25 | — | — | CN | claimed |
| CN-114621924-A | Porous carbon sphere nanoenzyme-doped hydrogen bond organic framework shell layer and preparation method thereof | 中国科学院长春应用化学研究所 | 2022-06-14 | — | — | CN | claimed |
| CN-111701458-B | Preparation method of covalent triazine framework organic solvent nanofiltration membrane | 北京工业大学 | 2022-02-15 | — | — | CN | claimed |
| CN-112058311-A | Preparation method and application of CTF (carbon nanotube) loaded nano-grade palladium particles | 昆明理工大学 | 2020-12-11 | — | — | CN | claimed |
| CN-111701458-A | Preparation method of covalent triazine framework organic solvent nanofiltration membrane | 北京工业大学 | 2020-09-25 | — | — | CN | claimed |
| CN-120082052-A | Mono-atom iron anchored covalent triazine skeleton and green synthesis method and application thereof | 杭州师范大学 | 2025-06-03 | — | — | CN | disclosed |
| CN-120005209-A | Photochromic hydrogen bond organic framework material and preparation method and application thereof | 陕西科技大学 | 2025-05-16 | — | — | CN | disclosed |
| CN-118198743-A | Nitrogen-containing covalent triazine frame type microwave absorbing carbon material and preparation method and application thereof | 西安交通大学 | 2024-06-14 | — | — | CN | disclosed |
| CN-114621924-B | Porous carbon sphere nano enzyme doped hydrogen bond organic framework shell and preparation method thereof | 中国科学院长春应用化学研究所 | 2024-05-17 | — | — | CN | disclosed |
| CN-116695171-A | Fe 3 C@C composite nano catalyst and preparation method and application thereof | 西华师范大学 | 2023-09-05 | — | — | CN | disclosed |
| CN-115386083-A | 3, 4-ethylenedioxythiophene covalent triazine framework and synthesis method and application thereof | 河南农业大学 | 2022-11-25 | — | — | CN | disclosed |
| CN-113845665-B | Full-conjugated organic triazine framework material and preparation method and application thereof | 天津大学 | 2022-11-08 | — | — | CN | disclosed |
| US-20120088758-A1 | FIVE-MEMBERED HETEROCYCLES USEFUL AS SERINE PROTEASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2012-04-12 | — | — | US | disclosed |
| US-8101778-B2 | Five-membered heterocycles useful as serine protease inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-01-24 | — | — | US | disclosed |
| US-20090036438-A1 | FIVE-MEMBERED HETEROCYCLES USEFUL AS SERINE PROTEASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-02-05 | — | — | US | disclosed |
| US-7453002-B2 | thrombotic or an inflammatory disorders; improved factor XIa and/or plasma kallikrein inhibitory activity and selectivity, dosage requirment, costs or feasibility, side effect reduction; 4-(aminomethyl)-N-[2-phenyl-1-(4-pyridin-2-yl-1H-imidazol-2-yl)ethyl]-trans-cyclohexanecarboxamide | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-11-18 | — | — | US | disclosed |
| EP-1773786-A2 | FIVE-MEMBERED HETEROCYCLES USEFUL AS SERINE PROTEASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2007-04-18 | — | — | EP | disclosed |
| WO-2005123050-A2 | FIVE-MEMBERED HETEROCYCLES USEFUL AS SERINE PROTEASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-12-29 | — | — | WO | disclosed |
| US-20050282805-A1 | thrombotic or an inflammatory disorders; improved factor XIa and/or plasma kallikrein inhibitory activity and selectivity, dosage requirment, costs or feasibility, side effect reduction; 4-(aminomethyl)-N-[2-phenyl-1-(4-pyridin-2-yl-1H-imidazol-2-yl)ethyl]-trans-cyclohexanecarboxamide | BRISTOL-MYERS SQUIBB COMPANY | 2005-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120088758-A1 | FIVE-MEMBERED HETEROCYCLES USEFUL AS SERINE PROTEASE INHIBITORS | F12, F11, F5 | TOP2A 4703/4885TOP2B 4432/4885PRSS1 19/4885 |
| US-20090036438-A1 | FIVE-MEMBERED HETEROCYCLES USEFUL AS SERINE PROTEASE INHIBITORS | F12, F11, F5 | TOP2A 4703/4885TOP2B 4432/4885PRSS1 19/4885 |
| US-20050282805-A1 | thrombotic or an inflammatory disorders; improved factor XIa and/or plasma kallikrein inhibitory activity and selectivity, dosage requirment, costs or feasibility, side effect reduction; 4-(aminomethyl)-N-[2-phenyl-1-(4-pyridin-2-yl-1H-imidazol-2-yl)ethyl]-trans-cyclohexanecarboxamide | F11, TFPI, F12 | TOP2A 4842/4885TOP2B 4795/4885PRSS1 20/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.